Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.35 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15958515 | 0.87 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL7831783 | 0.87 | CYP1A2 (0.62) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL24626778 | 0.87 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL9914279 | 0.85 | TSHR (0.38) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL8248035 | 0.85 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL8468137 | 0.85 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL7831780 | 0.85 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL3756921 | 0.85 | IDO1 (0.47) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL12251303 | 0.85 | CYP2A6 (0.59) | ALDH1A1TSHRTDP1KIF11CA2 | |
| SCHEMBL19440735 | 0.85 | KIF11 (0.41) | ALDH1A1TSHRTDP1KIF11CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330074-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | LEXICON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-7241857-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7173157-B2 | Method for producing an allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7119222-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330074-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | SMN1; SMN2, MUSK, GAB1 | ALDH1A1 3152/4885TSHR 4605/4885TDP1 791/4885 |
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | ALDH1A1 1665/4885TSHR 4449/4885TDP1 4654/4885 |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | ALDH1A1 1665/4885TSHR 4449/4885TDP1 4654/4885 |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | CCNT1, AOC3, ATL3 | ALDH1A1 790/4885TSHR 3258/4885TDP1 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.